摘要
目的探讨靶向血管内皮细胞生长因子(VEGF)基因的小干扰RNA(siRNA)联合负载肿瘤抗原的树突状细胞(DC)致敏的细胞毒性T淋巴细胞(CTL)的联合抗瘤作用。方法体外应用靶向VEGF基因最佳转染浓度(100nmol/L,增加浓度不再提高沉默作用)的siRNA联合负载人乳腺癌细胞(MCF-7细胞)抗原的DC介导的CTL(siRNAVEGF+CTL组)共同作用于MCF-7细胞,同时设立空白对照组和空白+CTL组(只加无血清无抗生素培养基);脂质体组和脂质体+CTL组(只加LipofectamineTM2000);siRNAVEGF-组(100nmol/LsiRNA);siRNASCR组和siR-NASCR+CTL组(100nmol/LsiRNASCR),每组做6个平行孔,四甲基偶氮唑蓝(MTT)法检测siRNAVEGF+CTL组和各对照组肿瘤杀伤活性(n=6),Hoechst33258核染色观察细胞的凋亡(n=3)。结果siRNAVEGF+CTL组、siR-NAVEGF-组siRNASCRCTL组肿瘤杀伤活性分别为99.37%,51.17%和43.94%,siRNAVEGF+CTL组与对照组比较可明显杀伤肿瘤细胞,瘤细胞几乎完全溶解,Hoechst33258显示细胞核呈明显的细胞凋亡改变。结论体外实验显示靶向VEGF的siRNA联合负载肿瘤抗原DC致敏的CTL能有效抑制乳腺癌MCF-7细胞的生长,二者的联合应用抗瘤效果显著。
Objective To investigate the effects of siRNA directed against VEGF gene and cytotoxic T lymphocyte(CTL)mediated by DCs loaded tumor-specific antigen on MCF-7 Breast Cancer cells.Medhods In vitro small interfering RNAs(siRNAs)directed against VEGF gene were designed and transfected into MCF-7 breast cancer cells at the optimal concentration(100 nmol/L)using cationic liposome Lipofectamine^TM 2000,then combinted CTL mediated by DCs(siRNAVEGF+CTL group)were used to against MCF-7 breast cancer cells.At the same time,the following groups were designed:blank control group and blank+CTL group(only with serum-free medium without antibiotics);liposome group and liposome+CTL group(added Lipofectamine^TM2000 only);siRNAVEGF-group and siRNAVEGF+CTL group(100 nmol/L siRNA);siRNASCR and siRNASCR+CTL group(100 nmol/L siRNASCR).Tumor killing effects in both siRNAVEGF+CTL group and control groups were measured by MTT(n=6)assay and Hoechst33258(n=3).Results The tumor killing effects in siRNAVEGF+CTL,siRNAVEGF and siRNASCR CTL groups were 99.37%,51.17% and 43.94%,respectively,obviously increased in siRNAVEGF+CTL group compared with the control groups(P〈0.01).The tumor cells were almost completely lysis and Hoechst33258 showed obviously apoptosis in nucleis in siRNAVEGF+CTL group.Conclusion The experiment demonstrated that siRNA directed against VEGF gene combined CTL mediated by DCs could inhibit the growth of MCF-7 cells,and with a more significant antitumor effect by the combined application.
出处
《中国输血杂志》
CAS
CSCD
北大核心
2010年第2期92-96,共5页
Chinese Journal of Blood Transfusion
基金
青岛市科技局科技计划项目(编号:07-2-1-7-nsh)